Ahead Therapeutics announces successful completion of its bridge financing round with Capital Cell. The company has secured an impressive 109% of its €1,200,000 funding goal, totaling €1,313,054.
This financing round, conducted through Capital Cell, a leading European Biotechnology crowdfunding investment platform, underscores the confidence in our vision and potential. The funding will be utilized to further develop and validate our innovative platform technology to potentially cure autoimmune diseases.
This achievement is a testament to our commitment to innovation and our capacity to deliver state-of-the-art solutions. We would like to extend our sincere gratitude to the 325 investors who believed in the potential of our treatment.